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Summary 
Background: Supragastric belching (SGB) has a significant behavioural 
component. We recently used cognitive behavioural therapy (CBT) to treat SGB. 
We demonstrated that CBT significantly reduces symptoms and improves quality 
of life in 50% of patients that completed treatment.  
 
Aims: To investigate factors associated to successful CBT for SGB and to assess 
symptoms 6-12 months after completion of CBT. 
 
Methods: Records of 39 patients who had completed the CBT protocol were 
analysed. Percent pre-to-post treatment change in symptoms was assessed 
using a Visual Analogue Scale (VAS) score. We evaluated the association 
between “pre-treatment” factors and “during treatment” factors, and symptomatic 
outcomes. Symptoms were also assessed 6-12 months after treatment. 
 
Results: From “pre-treatment factors”, a lower number of SGBs (P<0.01) and 
lower hypervigilance score (P<0.04) were significantly associated with better 
outcome. From “during treatment factors” a higher CBT “proficiency score” [a) 
acceptance of the explanation that SGB is a behavioural phenomenon b) 
detection of a warning signal before belching c) adherence to the exercises 
treatment] was associated with better outcome (P=0.001). Multiple regression 
analysis found that number of SGBs, hypervigilance score and CBT proficiency 
score were independently associated with outcome (P<0.01, P=0.01, P<0.01). 
VAS score before CBT (267 ± 79) decreased to 151 ± 88 soon after CBT 
(P<0.001), and the effect persisted at 6-12 months follow up (153 ± 82).  
 
Conclusions: Lower number of SGBs, lower hypervigilance score and higher 
patient’s proficiency during CBT were associated with better CBT outcome. CBT 
positive effect lasted at least 6-12 months post-treatment. 
 
Key words: supragastric belching, cognitive behavioural therapy, hypervigilance 
 
 
  
Introduction 
Impedance-pH monitoring can detect gastric belching and supragastric belching 
(SGB). Gastric belching is a physiological mechanism to vent swallowed air from 
the stomach whereas SGB involves an intake of air from the mouth/pharynx into 
the oesophagus, followed immediately by expelling the oesophageal air using 
abdominal straining 1. 
SGB often accompanies gastroesophageal reflux disease (GERD), functional 
dyspepsia and/or irritable bowel syndrome (IBS) 2-6. In some patients, SGB can 
induce gastroesophageal reflux 3,4. Excessive SGB has a profound impact on 
health-related quality of life 7,8.  
Pharmacological therapy for SGB includes use of Baclofen and Pregabalin. 
These drugs can partially decrease the number of SGBs 9,10, but their central side 
effects might preclude their chronic use. Previous studies have shown that 
cognitive behavioural therapy (CBT) can improve SGB 8,11-16. Recently, our group 
reported that CBT significantly reduces the number of SGBs and improves quality 
of life. Our 10 weeks CBT protocol consisted of explaining the possible 
mechanism of SGB, raising awareness of the physical initial warning signals 
preceding belching, and teaching patients abdominal breathing manoeuvres and 
a mouth/tongue position to prevent it 8. Half of our patients had a positive clinical 
response to CBT. Unlike pharmacotherapy, CBT does not cause side effects and 
its effect can last more than 6 months. On the other hand, CBT requires 
specialized clinical psychologists, a relative prolonged treatment and good 
patient’s compliance. Furthermore, such treatment is not readily available in many 
institutions worldwide. It could be therefore, clinically relevant and useful to be 
able to identify, beforehand, those patients that are more likely to respond to CBT.  
 
The aim of this study was to investigate factors contributing to successful CBT 
for SGB and to audit subjective outcomes at 6-12 months after completion of CBT. 
 
Materials and Methods 
Subjects 
Fifty-one consecutive patients [51% female, mean age 45 (20-72)] with 
pathological SGB (>13SGBs/24h) diagnosed by multichannel intraluminal 
impedance-pH monitoring (Sandhill Scientific, Inc, Highlands Ranch, CO, USA) 
were recruited at the Upper gastrointestinal Physiology Unit of the Royal London 
Hospital 8. Out of 51 patients referred to the CBT protocol, 12 patients did not 
complete the treatment. The remaining 39 patients who completed the 10-week 
CBT protocol were included in the current retrospective analysis. All of them had 
evaluation before and after treatment using a Visual analogue scale (VAS) for 
SGB symptoms severity (14), the Short Form Health Survey (SF-36), Big Five 
Inventory-10, and The Somatosensory Amplification Scale (Hypervigilance score). 
Thirty-one patients underwent a second impedance-pH monitoring after CBT.  
 
Subjective evaluation 
Visual analog scale (VAS) 
A four-item VAS, measured subjective changes in the severity of belching 
symptom throughout the intervention 14. Patients rated the following items from 0 
(absence of symptoms) to 100 (very severe symptoms) as follows; Q1. How 
bothered are you by your belching? Q2. How much can you control your 
belching? Q3. How much are your daily activities affected by your belching? Q4. 
How much are your social activities affected by your belching?  
VAS was recorded at 1st (Pre CBT), 3rd, 4th, and 5th (Post CBT) CBT sessions. 
Evaluation of VAS score was repeated 6 to 12 months after the end of CBT, 
through a telephone interview.  
 
Health related quality of life and personality assessment 
Health-related quality of life (HR-QOL) was assessed using the Short Form 
Health Survey (SF-36), which comprises eight domains as follows; physical 
functioning (daily life limitations due to health problems), bodily pain, limitations 
in fulfilling physical roles, general health and four psychological subscales of 
limitations in fulfilling emotional roles, vitality (energy/fatigue), social functioning 
and mental health. The scores of eight dimensions listed above were calculated 
using a dedicated algorithm ranging from 0 (where the respondent has the worst 
possible health) to 100 (where the respondent is in the best possible health) 17. 
The Big Five Inventory-10, a short version of the Big Five Inventory, was used to 
evaluate each patient’s personality. The dimensions of extraversion, 
agreeableness, conscientiousness, neuroticism, and openness were evaluated 
by 10 items with 5-point scale from 1 (disagree strongly) to 5 (agree strongly) 18. 
 
Hypervigilance score 
The Somatosensory Amplification Scale, a 10-item questionnaire, assesses 
hypervigilance to bodily sensations and the tendency to experience normal 
somatic sensations as uncomfortable or troubling 19. The items are rated on a 5-
point scale from 1 (Not at all true) to 5 (Extremely true) and ratings are summed 
to produce a total amplification score that ranges from 10 to 50 20, with average 
Somatosensory Amplification Scale scores between 24 and 29 21; scores higher 
than 30 may indicate increased somatization 22. 
 
Objective evaluation 
Impedance-pH was performed “off” PPI before and after CBT. Tracings were 
manually analysed for presence of acid/non-acid reflux and SGBs. SGBs were 
identified as previously described 1. In brief, a rapid rise in impedance (≥1000 Ω) 
moving in an aboral direction, followed by a return to baseline moving in the 
opposite direction. The total number of SGBs, acid and non-acid reflux episodes, 
and oesophageal acid exposure time (%) were calculated. 
 
Cognitive Behavioural Therapy 
The CBT program consisted of 5 sessions during 10 weeks. There was an initial 
assessment by a gastroenterologist and a psychologist that was followed by four 
sessions of CBT as previously describe 8. 
CBT can be divided into a cognitive and a behavioural component. The cognitive 
component helps patients to understand the subconscious abnormal behaviour 
underlying SGB, to learn how the CBT exercise mechanism can prevent SGB, 
and to recognize the triggering events (warning signal) preceding SGB. Most 
patients detect a physical tension in the epigastrium and/or chest as a warning 
signal. During the behavioural component, the therapist teaches the patients two 
treatment exercises as follows; (1) slow diaphragmatic breathing with inhaling for 
3 s and exhaling for 3 s, and (2) mouth opening/tongue position i.e. patients are 
asked to breathe through their mouth slightly open with their tongue touching the 
back of the top front teeth. They are required to practice these exercises at least 
twice per day for 3–5 min in a supine or sitting position until they get familiar and 
confident with the techniques. They are instructed to use these manoeuvres to 
prevent SGB as often as possible, especially when they feel the warning sign. 
 
Patient’s proficiency in CBT 
A proficiency score for CBT was developed to assess the patient’s understanding 
and implementation of the CBT exercises. The Proficiency Score (from 0 to 5) 
was assessed by CBT trained psychologists (EW and NA) and included the 
following items:   
a) Acceptance of the explanation that SGB is a behavioural phenomenon rather 
than an organic disease and understanding of the working mechanism of the 
exercises prescribed. This item was assessed at the end of the treatment (0= nil 
acceptance of SGB diagnosis and seeking further reasons to explain their 
belching or GI symptoms, 1= open to SGB diagnosis and completing treatment, 
yet some uncertainty/hesitation reported, 2= full acceptance of SGB diagnosis 
and treatment. 
b) The capacity of detection of a warning signal before belching was asked at the 
first CBT session. 0= no detection of any warning signals. 1= any warning signals 
were detected. 
c) Adherence to the exercise preventing SGBs reflected whether the patient 
completed the behavioural exercises between sessions (i.e. whether they used 
the diaphragmatic breathing to prevent and stop belching as instructed) and used 
correctly in the prescribed way. This was based on the patient's self-report to the 
psychologist; 0= no adherence to treatment instructions meaning a patient did 
not use the treatment instructions to prevent belching, 1= mostly adhered to 
treatment instructions with some difficulty with frequency or accuracy of the 
technique, 2= adhered to treatment instructions as instructed and with 
appropriate technique. 
 
Statistical analysis 
Data are expressed as median (interquartile range) or mean ± SD. The severity 
of belching symptoms was measured using VAS score in pre-CBT, during CBT 
sessions and in post-CBT. The aim of the analysis was to examine if there were 
factors associated with the change in the severity of belching symptoms from pre 
to post-treatment. This was analysed as a continuous score and was found to 
have an approximately normal distribution.  
 
Analyses examining factors associated with this outcome were performed in two 
stages. Firstly, the separate (univariable) association between each factor and 
the outcome was examined using linear regression. In the analysis for the 
association between CBT measurements and the percentage change in VAS 
score, each of the individual CBT components was assessed, along with the 
proficiency score for CBT. Patients with responses of zero for the acceptance and 
adherence components, were grouped with a score of 1 for analysis. The 
proficiency score was analysed as a continuous measurement and also split into 
categories. Subsequently, the joint association between the factors and outcome 
was assessed by multiple regression. To limit the number of factors in this stage 
of the analysis, only factors showing some association with the outcome in the 
univariable analyses (p<0.2) were included. A backwards selection procedure 
was performed to retain only the significant factors in the final model.  
 
Repeated measures ANOVA with Bonferroni post-hoc test was used to compare 
the VAS score during CBT sessions and among pre-CBT, post-CBT, and 6-12 
months after CBT. P <0.05 was considered statistically significant. 
Results 
Pre-treatment factors associated to CBT outcome 
Demographic and clinical data  
Out of 39 patients who completed the CBT session, 12 patients (31%) took 
standard dose of PPIs and 14 patients (36%) took double dose of PPIs at 
diagnosis. Twenty-three patients (59%) were native English speaker. Nine 
Patients (23%) had education to degree or above. Seventeen patients (44%) 
complained of belching as primary symptom and the duration of belching 
symptom was 2.5 years (1.5–4). In linear regression analysis, none of the 
demographic and clinical factors were found to be significantly associated with 
percentage change in VAS score (Table 1). 
 
Objective measurements; Impedance-pH monitoring 
The median number of SGBs was 103 (41–252) episodes. The median total 
number of reflux episodes was 49 (31–82) episodes, in which those of acid reflux 
was 37 (16–55) episodes. The median of total oesophageal acid exposure time 
was 3.8% (1.3–8.7) and 17 patients (44%) had pathological acid exposure (>6%) 
23. Linear regression analysis of the impedance-pH parameters showed that only 
the initial number of SGBs was significantly associated with percentage change 
in VAS score (Table 1). Due to the strongly positively skewed distribution of this 
score, this variable was analysed on the log scale. Patients with a lower number 
of SGBs before CBT were found to have a stronger percent decrease 
(improvement) of the VAS score after CBT (i.e. better outcome). (Figure 1A). 
 
Subjective measurements; Symptom severity, health-related quality of life, 
personality trait, and hypervigilance 
There was no significant association between percent change in VAS score from 
pre to post treatment and severity of VAS score at baseline or any of the initial 
SF-36 or Big Five Inventory-10 parameters (Table 2). However, hypervigilance 
score was found to be significantly associated (P=0.04). Higher hypervigilance 
score were associated with weaker percent decrease of the VAS score (less 
improvement) after CBT (i.e. worse outcome) (Figure 1B). 
 
During-treatment factors associated to CBT outcome 
Out of 39 patients, 32 patients (82%) could detect warning signals before belching. 
Four patients had throat symptoms, 25 patients had chest symptoms and 6 
patients had epigastric symptoms as warning signals.  
Neither the recognition of a warning signal or the acceptance of the behavioural 
character of their symptoms were significantly individually associated with better 
outcome. In contrast, the adherence to CBT exercises component was found to 
be significant. When the 3 components of the proficiency score were considered 
together (proficiency score), a higher score was associated with a stronger 
reduction of VAS score post treatment (improvement) (Figure 1C) (Table 3).  
 
Multivariate analysis using both pre- and during- CBT factors 
The number of pre-treatment SGBs, hypervigilance score and the CBT 
proficiency score were independently and significantly associated with the 
outcome. Higher values of both of the number of initial SGBs and hypervigilance 
score were associated with worse outcomes. On the contrary, higher CBT 
proficiency score was associated to better outcome. The R2 value was 49% 
suggesting that almost half of all variation in the outcome could be explained by 
these three factors (Table 4) 
 
Change of VAS score along the CBT sessions 
CBT improved VAS score gradually as the number of CBT sessions increased 
(Figure 2). Comparing VAS score between each two consecutive sessions, 
significant decreases of VAS score were shown both between pre-CBT and 3rd 
CBT session (261 ± 82 vs 210 ± 90, P<0.001) and between 4th CBT session and 
post-CBT (182 ± 84 vs 138 ± 84, P<0.001). 
 
Drop-out patients during CBT treatment 
12 patients (24%) dropped out during CBT treatment. The average number of 
CBT sessions which dropouts attended was 2 (1.8–3). Table 5 compares pre-
treatment and during treatment parameters between dropouts and those that 
completed treatment. The reasons for non-completion of treatment were lack of 
confidence (n=3), travelling difficulties (n=5) and preferred other treatments (n=4). 
There was no significant difference in age, gender, first language, degree of 
education, duration of belching symptom, initial severity of symptom and quality 
of life between dropouts and completers. The number of initial SGBs was 
numerically lower in dropouts but did not reach statistical significance. Only 
acceptance score during CBT was significantly lower in dropouts compared to 
those who completed CBT. 
 
Long-term outcome of CBT for SGB 
Thirty-one patients (79%) completed the telephone interview at 6-12 months after 
CBT, of which 24 patients (77%) stated that they continued to follow the CBT on 
a regular basis. Pre-CBT VAS score (267 ± 79) decreased to 151 ± 88 at the end 
of CBT (P<0.001). VAS score at the 6-12 months follow up (153 ± 82) were 
significantly lower than that of pre-CBT (P<0.001), and no significant difference 
was found between that of post-CBT and follow up at 6-12 months after CBT 
(P=1) (Figure 3). 
  
Discussion 
Cognitive behavioural therapy is a frequently used treatment for SGB 11-16. We 
have recently introduced CBT for SGB patients, obtaining a success rate of 
around 50% of our population that completed treatment. Identification of SGB 
patients that are more likely to respond to CBT could have significant clinical 
implications i.e. choice between pharmacological vs. CBT.  In this study, we 
aimed to identify the “pre-treatment” and “during-treatment” factors affecting the 
outcome of CBT. Our results showed (a) that the number of initial SGBs, 
hypervigilance score and a CBT proficiency score were independently associated 
with outcome (b) CBT exercises improved symptoms gradually as the number of 
CBT sessions increased, (c) the effect of CBT for SGB lasted at least 6-12 months.  
We used as outcome measure the subjective assessment of symptoms 
improvement rather than objective decrease of the number of SGBs. Acquiring 
self-confidence in controlling SGBs is probably more relevant for patients even if 
the number of SGBs did not significantly diminish 12,24.  
Previous studies assessed the effect of CBT in patients with SGB. Hemmink et 
al. 14 reported that 54.5% (6/11) of patients achieved >30% decrease of VAS 
score by 10 CBT sessions. Ong et al. 15 showed that 4 CBT sessions decreased 
VAS score by >50% in 55.6% (20/36) of patients. Also, Cate et al. 16 demonstrated 
that 5 sessions of speech therapy improved VAS score sufficiently in 60.4% 
(29/48) of the patients.  
In our study, a larger number of SGB and a higher score of hypervigilance were 
pre-treatment indicators of possible worse outcome. Similar results were 
suggested by studies in other functional GI disorders. A randomized control trial 
of CBT for functional bowel disorder demonstrated that participants with less 
severe illness responded better to treatment 25. 
. Although a relatively higher hypervigilance score was found in patients with 
worse response to CBT, the personality and hypervigilance scores of our sample 
did not differ from relevant population norms. 
 
The proficiency score comprised three key components of CBT as follows; (a) 
acceptance of explanation about SGB, (b) detection of warning signals, and (c) 
adherence to the exercise such as diaphragmatic breathing and mouth opening 
manoeuvre.  
The patients’ acceptance of behavioural explanation was a predictor of outcome. 
There is a possible barrier to accept that SGB could be a learned response if the 
suggestion is perceived as threatening or demeaning, e.g. if it is seen as blaming 
the patient for bringing about their symptoms themselves, or implying that the 
problem is ‘all in the mind’. Such perception might reduce engagement with 
treatment. 
The finding that patients who were able to identify warning signals preceding 
belching benefited from treatment is novel and may have practical implications. 
The variable was assessed at the first treatment session and so it could not have 
been affected by retrospective bias or self-selection. It is possible that patients 
could benefit from a list of signals that the successful patients pay attention to, 
and from being guided to learn to detect such warning signals themselves.  
The weight of adherence and acceptance was more important than the 
identification of the warning signal regarding the response to CBT. 
Although univariable analysis did not show significant association between 
detecting warning signals (isolated) and outcome, factors in the proficiency score 
have a profound mutual influence i.e. good acceptance and detecting warning 
signals can enhance patients’ adherence to the therapy 26,27.  
 
A high number of initial SGBs and hypervigilance score can be detected at the 
time of diagnosis of pathological SGB. On the other hand, a good proficiency 
score during CBT was associated with good outcome. These results might 
suggest that patients with poor pre-treatment parameters should either be treated 
with Baclofen or need more intensive and frequent CBT to improve proficiency.  
 
Our study had some limitations. Although the study included the largest number 
of SGB patients published so far, the sample size was still small. The analysis of 
parameters involved in CBT outcomes was based on our previous clinical study 
which lacked a control group either using pharmacotherapy (baclofen and/or 
pregabalin) or sham CBT 8. However, a recent randomised control trial comparing 
the effect of CBT versus no treatment on patients with SGBs did not show 
significant improvement in the no treatment group 15.  
We could not fully evaluate outcomes in dropout’s patients. The proficiency score 
might be biased because the psychologists rated it at the end of CBT where the 
therapist knew whether the patient improved or not; and the ratings were provided 
by the therapist, rather than by an independent observer.  However, ratings 
should be implemented only at the end of treatment because the patients’ 
proficiency for CBT got better by the increment of the number of CBT sessions 
they attended. Lastly, long-term follow-up did not examine the number of SGBs 
using impedance-pH monitoring at 6-12 month after CBT. 
 
In conclusion, the number of SGBs, hypervigilance score and CBT proficiency for 
SGB were factors that influenced treatment outcome. This result suggested that 
clinicians could detect patients with SGB who are less likely to respond to CBT 
at diagnosis. Based on this information, it is possible to modify the CBT intensity 
and duration to improve outcome.  
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Table 1 Univariable analysis of objective pre-CBT factors such as demographic and 
clinical characteristics and impedance-pH measurements 
Variable Coefficient (95% CI) P-value 
Age (years) † 
5 (-3, 12) 0.20 
Female -12 (-32, 9) 0.26 
Native English speaker -10 (-32, 11) 0.33 
Education to degree or above -5 (-30, 20) 0.71 
Primary symptom (belch)  -15 (36, 6) 0.16 
Duration of belching symptom (years) 0 (-3, 3) 0.92 
impedance-pH measurements   
Number of SGBs ‡ 25 (7, 41) 0.006 
Total reflux § 1 (-2, 4) 0.62 
Acid reflux § 3 (-1, 6) 0.19 
Non-acid reflux § -2 (-7, 3) 0.41 
Total acid exposure time (%) ¶ 3 (-9, 14) 0.64 
Upright acid exposure time (%) ¶ 4 (-5, 12) 0.37 
Recumbent acid exposure time (%) ¶ -2 (-11, 7) 0.68 
† Regression coefficient given for a 10-year increase in age 
‡ Variable analysed on the log scale (base 10) 
§ Regression coefficients given for a 10-unit increase in variable 
¶ Regression coefficients given for a 5-unit increase in variable 
CBT, cognitive behaviour therapy; SGBs, supragastric belchings; CI, confidence interval. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Univariable analysis of subjective pre-CBT factors such as symptom severity, 
quality of life, personality trait, and hypervigilance 
Variable Coefficient (95% CI) P-value 
VAS score at baseline † -1 (-8, 5) 0.65 
SF-36   
  Physical functioning ‡ -1 (-4, 3) 0.68 
  Role limitation physical ‡ -1 (-4, 1) 0.29 
  Bodily pain ‡ 0 (-4, 3) 0.92 
  General health perceptions ‡ 1 (-4, 6) 0.71 
  Vitality ‡ 2 (-3, 6) 0.49 
  Social functioning ‡ -2 (-6, 2) 0.22 
  Role-emotional ‡ -2 (-4, 1) 0.13 
  Mental health ‡ -1 (-5, 4) 0.79 
Big Five Inventory-10   
  Extraversion  2 (-10, 14) 0.75 
  Agreeableness -7 (-21, 8) 0.37 
  Conscientiousness -7 (-21, 8) 0.38 
  Neuroticism -7 (-16, 2) 0.13 
  Openness -4 (-16, 9) 0.53 
Hypervigilance score (SSAS) § 7 (0, 13) 0.04 
† Regression coefficients given for a 50-unit increase in variable 
‡ Regression coefficients given for a 10-unit increase in variable 
§ Regression coefficients given for a 5-unit increase in variable 
CBT, cognitive behaviour therapy; VAS, Visual analogue scale; SF-36, the Short Form 
Health Survey; SSAS, Somatosensory Amplification Scale; CI, confidence interval. 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Univariable analyses of during CBT factors 
Variable Coefficient (95% CI) P-value 
Individual CBT components   
Warning signal -17 (-44, 10) 0.22 
Acceptance (Score 2) -18 (-38, 3) 0.09 
Adherence (Score 2) -34 (-6, -13) 0.002 
   
Proficiency score for CBT (continuous) -11 (-17, -5) 0.001 
Proficiency score for CBT (categorical)                    0.01 
Score 0 – 2  0  
   Score 3 – 4  -28 (-54, -1)  
   Score 5 -38 (-62, -13)  
CBT, cognitive behaviour therapy; CI, confidence interval. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 Multivariable model 
Variable Coefficient (95% CI) P-value Model R2 
Number of SGBs † 25 (10, 40) 0.002 49% 
Hypervigilance score (SSAS) ‡ 7 (2, 13) 0.01  
Proficiency score for CBT -8 (-13, -2) 0.008  
† Variable analysed on the log scale (base 10) 
‡ Regression coefficients given for a 5-unit increase in variable 
SGBs, supragastric belchings; SSAS, Somatosensory Amplification Scale; CBT, 
cognitive behaviour therapy; CI, confidence interval. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5 Demographic and clinical characteristics, quality of life and during-CBT factors 
in patients who completed and dropped out of CBT. 
 Subjects who 
completed CBT 
N=39 
Dropouts 
N=12 
P-value 
Age (years) 46 (32–56) 47 (35–51) 0.97 
Female (%) 20 (51.3) 4 (33.3) 0.34 
Native English speaker (%) 23 (59.0) 8 (66.7) 0.74 
Education to degree or above (%) 9 (23.1) 3 (25.0) 1 
Duration of belching symptom 
(years) 
2.5 (1.5–4) 2.8 (2–3.5) 0.57 
Number of SGBs 114 (44–228) 55 (33–76) 0.07 
VAS score at baseline 6.5 (5.4-8) 7.8 (6.5-9) (N=9) 0.20 
SF-36    
  Physical functioning 65 (35–89) 80 (64–96) 0.23 
  Role limitation physical 50 (0–100) 38 (0–75) 0.42 
  Bodily pain 45 (24–78) 68 (30–78) 0.71 
  General health perceptions 45 (30–60) 43 (19–58) 0.56 
  Vitality 50 (28–58) 55 (44–60) 0.45 
  Social functioning 63 (38–75) 63 (38–75) 0.96 
  Role-emotional 100 (33–100) 67 (50–100) 0.56 
  Mental health 64 (48–80) 62 (54–68) 0.71 
During-CBT factors    
Warning signal (%) 32 (82.1) 7 (58.3) 0.12 
Acceptance 1 (1–2) 0 (0–1) 0.004 
CBT, cognitive behaviour therapy; SGBs, supragastric belchings; VAS, Visual analogue 
scale; SF-36, the Short Form Health Survey. 
 
 
 
 
 
 
 
 
 
Figure legends 
Figure 1 Association between number of SGBs, Hypervigilance score, and CBT 
proficiency score and percent change in VAS score 
Note that in the graph the number of SGBs is shown on the log scale (A). The 
fitted regression lines are represented as red line. High number of SGBs (A) and 
hypervigilance score (SSAS) (B) were associated with large percent change of 
VAS score (i.e. worse outcome). On the contrary, high total proficiency score (on 
a continuous scale) was related to smaller percent change of VAS score (i.e. 
better outcome) (C). 
SGB, supragastric belching; SSAS, Somatosensory Amplification Scale; CBT, 
cognitive behavioral therapy; VAS, Visual analogue scale. 
 
 
Figure 2 Shift of VAS score from baseline during the CBT sessions 
VAS score gradually decreased as the CBT sessions progressed. VAS score at 
3rd session was significantly smaller than those at Pre-CBT. Similarly, post-CBT 
showed significantly smaller VAS score compared to 4th CBT session. 
VAS, Visual analogue scale; CBT, cognitive behavioral therapy. 
* p<0.001 
 
 
Figure 3 Long-term outcome of CBT for SGB 
CBT significantly improved VAS score not only at just after the treatment sessions. 
This effect lasted 6 to 12 months after the treatment as no significant change was 
observed between just post-CBT and follow-up at 6-12months after CBT. 
CBT, cognitive behavioral therapy; SGB, supragastric belching; VAS, Visual 
analogue scale. 
* p<0.001 versus pre-CBT 
 
